Page 2222 - Williams Hematology ( PDFDrive )

2196 Part XII: Hemostasis and Thrombosis Chapter 128: Hemostatic Alterations in Liver Disease and Liver Transplantation 2197

79. Gazzard BG, Henderson JM, Williams R: The use of fresh frozen plasma or a concen- 102. Bechmann LP, Sichau M, Wichert M, et al: Low-molecular-weight heparin in patients
trate of factor IX as replacement therapy before liver biopsy. Gut 16(8):621–625, 1975. with advanced cirrhosis. Liver Int 31(1):75–82, 2011.
80. Alter HJ, Klein HG: The hazards of blood transfusion in historical perspective. Blood 103. Cerini F, Garcia-Pagán JC: Tromboprophylaxis with heparin in hospitalized patients
112(7):2617–2626, 2008. with cirrhosis: Friend or foe. Liver Int 34(7):971–973, 2014.
81. Rockey DC, Caldwell SH, Goodman ZD, et al: American Association for the Study of 104. Intagliata NM, Henry ZH, Shah N, et al: Prophylactic anticoagulation for venous
Liver Diseases: Liver biopsy. Hepatology 49(3):1017–1044, 2009. thromboembolism in hospitalized cirrhosis patients is not associated with high rates of
82. Liumbruno G, Bennardello F, Lattanzio A, et al: Recommendations for the transfusion gastrointestinal bleeding. Liver Int 34(1):26–32, 2014.
of plasma and platelets. Blood Transfus 7(2):132–150, 2009. 105. Potze W, Arshad F, Adelmeijer J, et al: Routine coagulation assays underestimate levels
83. Saja MF, Abdo AA, Sanai FM, et al: The coagulopathy of liver disease: Does vitamin K of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from
help? Blood Coagul Fibrinolysis 24(1):10–17, 2013. patients with cirrhosis. Br J Haematol 163(5):666–673, 2013.
84. Boberg KM, Brosstad F, Egeland T, et al: Is a prolonged bleeding time associated with an 106. Amitrano L, Brancaccio V, Guardascione MA, et al: Inherited coagulation disorders in
increased risk of hemorrhage after liver biopsy? Thromb Haemost 81(3):378–381, 1999. cirrhotic patients with portal vein thrombosis. Hepatology 31(2):345–348, 2000.
85. Agnelli G, Parise P, Levi M, et al: Effects of desmopressin on hemostasis in patients with 107. Zocco MA, Di Stasio E, De Cristofaro R, et al: Thrombotic risk factors in patients with
liver cirrhosis. Haemostasis 25(5):241–247, 1995. liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis
86. Wong AY, Irwin MG, Hui TW, et al: Desmopressin does not decrease blood loss and development. J Hepatol 51(4):682–689, 2009.
transfusion requirements in patients undergoing hepatectomy. Can J Anaesth 50(1): 108. Okuda K, Ohnishi K, Kimura K, et al: Incidence of portal vein thrombosis in liver cir-
14–20, 2003. rhosis. An angiographic study in 708 patients. Gastroenterology 89(2):279–286, 1985.
87. de Franchis R, Arcidiacono PG, Carpinelli L, et al: Randomized controlled trial of 109. Senzolo M, M Sartori T, Rossetto V, et al: Prospective evaluation of anticoagulation
desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal and transjugular intrahepatic portosistemic shunt for the management of portal vein
hemorrhage in cirrhotic patients: A multicenter, double-blind study. New Italian Endo- thrombosis in cirrhosis. Liver Int 32(6):919–927, 2012.
scopic Club. Hepatology 18(5):1102–1107, 1993. 110. Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al: Acute portal vein throm-
88. Sharma P, McDonald GB, Banaji M: The risk of bleeding after percutaneous liver bosis unrelated to cirrhosis: A prospective multicenter follow-up study. Hepatology
biopsy: Relation to platelet count. J Clin Gastroenterol 4(5):451–453, 1982. 51(1):210–218, 2010.
89. Lisman T, Caldwell SH, Burroughs AK, et al: Hemostasis and thrombosis in patients 111. Confer BD, Hanouneh I, Gomes M, Alraies MC: Q: Is anticoagulation appropriate for
with liver disease: The ups and downs. J Hepatol 53(2):362–371, 2010. all patients with portal vein thrombosis? Cleve Clin J Med 80(10):611–613, 2013.
90. Violi F, Basili S, Raparelli V, et al: Patients with liver cirrhosis suffer from primary hae- 112. Intagliata N, Maitland H, Northup P, Caldwell S: Treating thrombosis in cirrhosis
mostatic defects? Fact or fiction? J Hepatol 55(6):1415–1427, 2011. patients with new oral agents: Ready or not? Hepatology 61(2):738–739, 2015.
91. Slichter SJ: Evidence-based platelet transfusion guidelines. Hematology Am Soc 113. Washington K: Update on post-liver transplantation infections, malignancies, and sur-
Hematol Educ Program 2007:172–178. gical complications. Adv Anat Pathol 12(4):221–226, 2005.
92. Afdhal NH, Giannini EG, Tayyab G, et al: Eltrombopag before procedures in patients 114. Silva MA, Jambulingam PS, Gunson BK, et al: Hepatic artery thrombosis following
with cirrhosis and thrombocytopenia. N Engl J Med 367(8):716–724, 2012. orthotopic liver transplantation: A 10-year experience from a single centre in the
93. Lisman T, Porte RJ: Eltrombopag before procedures in patients with cirrhosis and United Kingdom. Liver Transpl 12(1):146–151, 2006.
thrombocytopenia. N Engl J Med 367(21):2055–2056, 2012. 115. Bekker J, Ploem S, de Jong KP: Early hepatic artery thrombosis after liver transplanta-
94. de Boer MT, Boonstra EA, Lisman T, Porte RJ: Role of fibrin sealants in liver surgery. tion: A systematic review of the incidence, outcome and risk factors. Am J Transplant
Dig Surg 29(1):54–61, 2012. 9(4):746–757, 2009.
95. Wang SC, Shieh JF, Chang KY, et al: Thromboelastography-guided transfusion decreases 116. Quiroga S, Sebastia MC, Margarit C, et al: Complications of orthotopic liver transplan-
intraoperative blood transfusion during orthotopic liver transplantation: Randomized tation: Spectrum of findings with helical CT. Radiographics 21(5):1085–1102, 2001.
clinical trial. Transplant Proc 42(7):2590–2593, 2010. 117. Hirshfield G, Collier JD, Brown K, et al: Donor factor V Leiden mutation and vascular
96. Porte RJ, Molenaar IQ, Begliomini B, et al: Aprotinin and transfusion requirements thrombosis following liver transplantation. Liver Transpl Surg 4(1):58–61, 1998.
in orthotopic liver transplantation: A multicentre randomised double-blind study. 118. Vivarelli M, La Barba G, Cucchetti A, et al: Can antiplatelet prophylaxis reduce the
EMSALT Study Group. Lancet 355(9212):1303–1309, 2000. incidence of hepatic artery thrombosis after liver transplantation? Liver Transpl 13(5):
97. Boylan JF, Klinck JR, Sandler AN, et al: Tranexamic acid reduces blood loss, transfusion 651–654, 2007.
requirements, and coagulation factor use in primary orthotopic liver transplantation. 119. Warnaar N, Molenaar IQ, Colquhoun SD, et al: Intraoperative pulmonary embolism
Anesthesiology 85(5):1043–1048; discussion 30A–31A, 1996. and intracardiac thrombosis complicating liver transplantation: A systematic review.
98. Fergusson DA, Hebert PC, Mazer CD, et al: A comparison of aprotinin and lysine ana- J Thromb Haemost 6(2):297–302, 2008.
logues in high-risk cardiac surgery. N Engl J Med 358(22):2319–2331, 1996. 120. Jairath V, Burroughs AK: Anticoagulation in patients with liver cirrhosis: Complication
99. Tripodi A, Anstee QM, Sogaard KK, et al: Hypercoagulability in cirrhosis: Causes and or therapeutic opportunity? Gut 62(4):479–482, 2013.
consequences. J Thromb Haemost 9(9):1713–1723, 2011. 121. Wright M, Goldin R, Hellier S, et al: Factor V Leiden polymorphism and the rate of
100. Northup PG, Sundaram V, Fallon MB, et al: Hypercoagulation and thrombophilia in fibrosis development in chronic hepatitis C virus infection. Gut 52(8):1206–1210, 2003.
liver disease. J Thromb Haemost 6(1):2–9, 2008. 122. Papatheodoridis GV, Papakonstantinou E, Andrioti E, et al: Thrombotic risk factors
101. Villa E, Camma C, Marietta M, et al: Enoxaparin prevents portal vein thrombo- and extent of liver fibrosis in chronic viral hepatitis. Gut 52(3):404–409, 2003.
sis and liver decompensation in patients with advanced cirrhosis. Gastroenterology
143(5):1253–1260, 2012.

Kaushansky_chapter 128_p2191-2198.indd 2197 9/18/15 10:38 AM